US EditionValneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
3 Articles
3 Articles
Valneva Reports Positive Results for Phase 1 Trial of Second-Generation Zika Vaccine Candidate
Immune response successfully improved with second generation vaccine candidate Saint-Herblain (France), November 4, 2025 – Valneva SE (NASDAQ:VALN, PARIS:VLA), a specialty vaccine company, today announced positive results of its Phase 1 clinical trial investigating the safety and immunogenicity of VLA1601, its second-generation adjuvanted inactivated vaccine candidate against the Zika virus (ZIKV). The randomized controlled Phase 1 trial, VLA160…
Valneva announces positive data for VLA1601 in Phase I trial
Valneva has reported encouraging results from a Phase I clinical trial assessing the immunogenicity and safety of its second generation Zika vaccine candidate, VLA1601.The post Valneva announces positive data for VLA1601 in Phase I trial appeared first on Clinical Trials Arena.
Coverage Details
Bias Distribution
- 50% of the sources are Center, 50% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
